News

FDA chooses Dr. Vinay Prasad to lead biologics, vaccines division
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
Axios on MSN13d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Wellbeing Whisper on MSN23h
Why Most Americans Won't Need Covid Boosters Anymore and What It Means for You
We want to know more about what these products are doing,” said Dr. Vinay Prasad during a recent FDA livestreamed ...
BioPharma Dive13d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Scripps News on MSN15d
Drug industry critic Vinay Prasad will lead FDA's vaccine oversight
Vinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and gene therapy regulation.
BioSpace13d
Vinay Prasad’s FDA Appointment ‘Anything but Status Quo’
The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...
Science-Based Medicine12dOpinion
Dr. Vinay Prasad is Now the Medical Establishment. It’s His Job to Run RCTs, and It’s Our Job to Call Him a Lying Piece of $#!& if He Fails.
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
New Republic3d
An Anti-Science MAHA Extremist Is Playing a Major Role at the FDA
If there’s anything that Dr. Vinay Prasad, the controversial new appointee to lead the Center for Biologics Evaluation and Research, or CBER, a top office at the Food and Drug Administration ...
BioSpace8d
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
FiercePharma1d
FDA lays out stricter COVID vaccine policy in pivot from 'one-size-fits-all' approach
FDA Commissioner Marty Makary, M.D., and Center for Biologics Evaluation and Research (CBER) head Vinay Prasad, M.D., laid out the agency's “evidence-based approach to COVID-19 vaccination” in ...
MedPage Today on MSN13dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...